COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. (11th October 2021)

• Record Type: Journal Article
• Authors: Breccia, Massimo; Abruzzese, Elisabetta; Accurso, Vincenzo; Attolico, Immacolata; Barulli, Sara; Bergamaschi, Micaela; Binotto, Gianni; Bocchia, Monica; Bonifacio, Massimiliano; Caocci, Giovanni; Capodanno, Isabella; Castagnetti, Fausto; Cavazzini, Francesco; Crisà, Elena; Crugnola, Monica; Stella De Candia, Maria; Elena, Chiara; Fava, Carmen; Galimberti, Sara; Gozzini, Antonella; Gugliotta, Gabriele; Intermesoli, Tamara; Iurlo, Alessandra; La Barba, Gaetano; Latagliata, Roberto; Leonetti Crescenzi, Sabrina; Levato, Luciano; Loglisci, Giuseppina; Lucchesi, Alessandro; Luciano, Luigiana; Lunghi, Francesca; Luzi, Debora; Malato, Alessandra; Cristina Miggiano, Maria; Pizzuti, Michele; Pregno, Patrizia; Rapezzi, Davide; Rege‐Cambrin, Giovanna; Rosti, Gianantonio; Russo, Sabina; Sancetta, Rosaria; Rita Scortechini, Anna; Sorà, Federica; Sportoletti, Paolo; Stagno, Fabio; Tafuri, Agostino; Tiribelli, Mario; Foà, Robin; Saglio, Giuseppe;
• Is Part Of: British journal of haematology. Volume 196:Number 3(2022)
• Page Start: 559
• Page End: 565
• Publication Date: 2021-10-11
• Subjects: chronic myeloid leukemia -- Covid‐19 -- prognosis -- mortality; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17890
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Limited information is available on the impact of the COVID‐19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS‐CoV‐2‐positive patients (2·5%). Most patients (57%) were diagnosed as having SARS‐CoV‐2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty‐six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS‐CoV‐2 infection was six years (three months to 18 years). Twenty‐one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty‐three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID‐19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS‐CoV‐2 infection and an impact of the pandemic on the overall management of CML patients.